首页> 美国卫生研究院文献>Oncotarget >IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients

【2h】

IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients

机译：IL-8和eNOS多态性可预测RAS突变转移性结直肠癌患者基于贝伐单抗的一线治疗结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

BackgroundPredictive biomarkers of efficacy and toxicity of bevacizumab have not yet been validated. This study assessed the influence of IL-8, eNOS and VEGF-A polymorphisms in RAS mutated metastatic colorectal cancer patients receiving bevacizumab-based chemotherapy.

机译：背景：贝伐单抗功效和毒性的预测性生物标志物尚未得到验证。这项研究评估了IL-8，eNOS和VEGF-A多态性对接受贝伐单抗化疗的RAS突变转移性结直肠癌患者的影响。

著录项

期刊名称 Oncotarget
作者
Mariantonietta Di Salvatore; Filippo Pietrantonio; Armando Orlandi; Marzia Del Re; Rosa Berenato; Ernesto Rossi; Marta Caporale; Donatella Guarino; Antonia Martinetti; Michele Basso; Roberta Mennitto; Concetta Santonocito; Alessia Mennitto; Giovanni Schinzari; Ilaria Bossi; Ettore Capoluongo; Romano Danesi; Filippo de Braud; Carlo Barone;
展开▼
作者单位

展开▼
年(卷),期 2017(8),10
年度 2017
页码 16887–16898
总页数 12
原文格式 PDF
正文语种
中图分类肿瘤学;细胞生物学;
关键词
single nucleotid polymorphisms bevacizumab IL-8 eNOS colorectal cancer;

机译：单核苷酸多态性;贝伐单抗;IL-8;eNOS;结直肠癌;

相似文献

外文文献
中文文献
专利

1. eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial [J] . Paola Ulivi, Emanuela Scarpi, Alessandro Passardi, Journal of Translational Medicine . 2015,第1期

机译：eNOS多态性可作为基于贝伐单抗的化学疗法在转移性结直肠癌中的疗效预测指标：来自一项随机临床试验的数据
2. Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials [J] . Sunakawa Y., Stintzing S., Cao S., Annals of oncology: official journal of the European Society for Medical Oncology . 2015,第12期

机译：调节肿瘤相关巨噬细胞（TAM）的基因变异预测转移性结直肠癌患者基于贝伐单抗的治疗结果：TRIBE和FIRE3试验的结果
3. CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy [J] . Matsusaka S., Cao S., Hanna D. L., The pharmacogenomics journal . 2017,第6期

机译：CXCR4多态性预测，通过一线贝伐单抗化疗治疗的转移性结直肠癌患者的无进展生存
4. Applying Quantitative Adiposity Feature Analysis Models to Predict Benefit of Bevacizumab-based Chemotherapy in Ovarian Cancer Patients [C] . Yunzhi Wang, Yuchen Qiu, Theresa Thai, Conference on medical imaging . 2016

机译：应用定量肥胖特征分析模型预测基于贝伐单抗的卵巢癌化疗获益
5. Evaluating response to treatment and predicting outcome in patients with metastatic colorectal carcinoma using statistical learning theory . [D] . Margolis, Daniel Eli. 2010

机译：运用统计学习理论评价转移性大肠癌患者的治疗反应和预测结局。
6. VEGF-A and ICAM-1 Gene Polymorphisms as Predictors of Clinical Outcome to First-Line Bevacizumab-Based Treatment in Metastatic Colorectal Cancer [O] . Apostolos Papachristos, Polychronis Kemos, Theodora Katsila, 2019

机译：VEGF-A和ICAM-1基因多态性作为基于贝伐单抗一线治疗转移性结直肠癌临床疗效的预测指标
7. eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: Data from a randomized clinical trial [O] . Ulivi, Paola, Scarpi, Emanuela, Passardi, Alessandro, 2015

机译：eNOS多态性可作为基于贝伐单抗的化学疗法治疗转移性结直肠癌疗效的预测指标：来自一项随机临床试验的数据

IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅